Advertisement

dermwire-tv-logo Created with Sketch.
dermwire-tv-logo Created with Sketch.

FDA Warns on Expression; Lilly's Ixekizumab Data Promising

Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.

Advertisement

In This Series

View More

Advertisement